# Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

> **NCT02320292** · PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- Ann Arbor Stage I Grade 2 Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma

## Interventions

- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Rituximab
- **RADIATION:** Yttrium Y-90 Ibritumomab Tiuxetan

## Key facts

- **NCT ID:** NCT02320292
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-11
- **Primary completion:** 2021-02-28
- **Final completion:** 2023-11-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** drug supply issues
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320292, "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02320292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*